ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,048.42
      -0.46%
      US Tech 100
      17,168.35
      0.63%
      Dow Jones
      38,085.80
      -0.98%
      Brent Oil
      88.105
      -0.05%
      Bitcoin
      64,236.62
      -0.38%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. TG Therapeutics Inc (TGTX)

      7. TG Therapeutics Inc (TGTX) News

      TGTX

      TG Therapeutics (TGTX)

      TG Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:TGTX
      DateTimeSourceHeadlineSymbolCompany
      12:52PMiHub NewswireFeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
      04/18/20247:30AMGlobeNewswire Inc.TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
      04/18/20247:00AMGlobeNewswire Inc.TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple SclerosisNASDAQ:TGTXTG Therapeutics Inc
      04/15/20247:30AMGlobeNewswire Inc.TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
      03/08/20247:30AMGlobeNewswire Inc.TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
      03/01/20247:30AMGlobeNewswire Inc.TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNASDAQ:TGTXTG Therapeutics Inc
      02/29/20245:23PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TGTXTG Therapeutics Inc
      02/28/20247:24AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TGTXTG Therapeutics Inc
      02/28/20247:00AMGlobeNewswire Inc.TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:TGTXTG Therapeutics Inc
      02/27/20247:30AMGlobeNewswire Inc.TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)NASDAQ:TGTXTG Therapeutics Inc
      02/26/20247:00AMGlobeNewswire Inc.TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)NASDAQ:TGTXTG Therapeutics Inc
      02/23/20247:30AMGlobeNewswire Inc.TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business UpdateNASDAQ:TGTXTG Therapeutics Inc
      02/20/20247:30AMGlobeNewswire Inc.TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNASDAQ:TGTXTG Therapeutics Inc
      02/14/20249:53PMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:TGTXTG Therapeutics Inc
      02/14/20243:30PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TGTXTG Therapeutics Inc
      01/26/20244:23PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TGTXTG Therapeutics Inc
      01/10/20247:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TGTXTG Therapeutics Inc
      01/10/20247:00AMGlobeNewswire Inc.TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated MilestonesNASDAQ:TGTXTG Therapeutics Inc
      01/09/20249:20AMAllPennyStocks.comBiotech Massively Bid Up Before Opening BellNASDAQ:TGTXTG Therapeutics Inc
      01/09/20247:00AMGlobeNewswire Inc.TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune DiseasesNASDAQ:TGTXTG Therapeutics Inc
      01/08/20246:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TGTXTG Therapeutics Inc
      01/08/20246:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TGTXTG Therapeutics Inc
      01/05/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TGTXTG Therapeutics Inc
      01/05/202411:02AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TGTXTG Therapeutics Inc
      01/05/20247:30AMGlobeNewswire Inc.TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TGTXTG Therapeutics Inc
      01/03/20244:46PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TGTXTG Therapeutics Inc
      11/27/20237:30AMGlobeNewswire Inc.TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TGTXTG Therapeutics Inc
      11/06/20235:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TGTXTG Therapeutics Inc
      11/03/20237:30AMGlobeNewswire Inc.TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:TGTXTG Therapeutics Inc
      11/01/20237:33AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TGTXTG Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:TGTX